Study effect of MAPA-VIP on control of allergic asthma pathophysiology

INTRODUCTION: Asthma is a pulmonary disease and its pathogenesis is involved with immune cells and related signalling pathways. Alpha-alumina is material for therapy applications and mucus adhesion promoting protein is cell-surface protein. Vasoactive intestinal peptide (VIP) exerts immunomodulation...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Weihong, Yang, Dongcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485757/
https://www.ncbi.nlm.nih.gov/pubmed/37692278
http://dx.doi.org/10.5114/ada.2023.129458
_version_ 1785102857858449408
author Jia, Weihong
Yang, Dongcai
author_facet Jia, Weihong
Yang, Dongcai
author_sort Jia, Weihong
collection PubMed
description INTRODUCTION: Asthma is a pulmonary disease and its pathogenesis is involved with immune cells and related signalling pathways. Alpha-alumina is material for therapy applications and mucus adhesion promoting protein is cell-surface protein. Vasoactive intestinal peptide (VIP) exerts immunomodulation. Therefore, the drug delivery system and target binding molecule could be applicable for treatment of asthma. MATERIAL AND METHODS: VIP-MapA-α-alumina was administered to asthmatic mice. Then, eosinophil percentage, IgE, IL-4, IL-5, and IL-13 levels, GATA3, and MUC5AC gene expression, ROS and lung histopathology were studied. RESULTS: Eosinophil percentage, IgE, IL-4, IL-5, IL-13, and ROS levels, expression of GATA3 and MUC5AC genes, goblet cell hyperplasia, mucus hyper-production, perivascular and peribronchial inflammation were decreased in VIP and VIP-MapA treated groups and treatment with VIP-MapA has a stronger effect than VIP alone. CONCLUSIONS: The delivery system of VIP carrying to the lung with the use of MapA as an adhesion molecule, could easily carry VIP and led to penetration of this component to the mucus and reach bronchial cells and present an effective, strong, and long-acting effect on therapy of asthma.
format Online
Article
Text
id pubmed-10485757
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-104857572023-09-09 Study effect of MAPA-VIP on control of allergic asthma pathophysiology Jia, Weihong Yang, Dongcai Postepy Dermatol Alergol Original Paper INTRODUCTION: Asthma is a pulmonary disease and its pathogenesis is involved with immune cells and related signalling pathways. Alpha-alumina is material for therapy applications and mucus adhesion promoting protein is cell-surface protein. Vasoactive intestinal peptide (VIP) exerts immunomodulation. Therefore, the drug delivery system and target binding molecule could be applicable for treatment of asthma. MATERIAL AND METHODS: VIP-MapA-α-alumina was administered to asthmatic mice. Then, eosinophil percentage, IgE, IL-4, IL-5, and IL-13 levels, GATA3, and MUC5AC gene expression, ROS and lung histopathology were studied. RESULTS: Eosinophil percentage, IgE, IL-4, IL-5, IL-13, and ROS levels, expression of GATA3 and MUC5AC genes, goblet cell hyperplasia, mucus hyper-production, perivascular and peribronchial inflammation were decreased in VIP and VIP-MapA treated groups and treatment with VIP-MapA has a stronger effect than VIP alone. CONCLUSIONS: The delivery system of VIP carrying to the lung with the use of MapA as an adhesion molecule, could easily carry VIP and led to penetration of this component to the mucus and reach bronchial cells and present an effective, strong, and long-acting effect on therapy of asthma. Termedia Publishing House 2023-09-01 2023-08 /pmc/articles/PMC10485757/ /pubmed/37692278 http://dx.doi.org/10.5114/ada.2023.129458 Text en Copyright: © 2023 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Jia, Weihong
Yang, Dongcai
Study effect of MAPA-VIP on control of allergic asthma pathophysiology
title Study effect of MAPA-VIP on control of allergic asthma pathophysiology
title_full Study effect of MAPA-VIP on control of allergic asthma pathophysiology
title_fullStr Study effect of MAPA-VIP on control of allergic asthma pathophysiology
title_full_unstemmed Study effect of MAPA-VIP on control of allergic asthma pathophysiology
title_short Study effect of MAPA-VIP on control of allergic asthma pathophysiology
title_sort study effect of mapa-vip on control of allergic asthma pathophysiology
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485757/
https://www.ncbi.nlm.nih.gov/pubmed/37692278
http://dx.doi.org/10.5114/ada.2023.129458
work_keys_str_mv AT jiaweihong studyeffectofmapaviponcontrolofallergicasthmapathophysiology
AT yangdongcai studyeffectofmapaviponcontrolofallergicasthmapathophysiology